At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 107 enrolled
Drug / intervention
Leuprolidedrug
Likely dose
Leuprolide (ELIGARD) - subcutaneous injection, dose not specified in criteria or armsAI-extracted
Key inclusion· 4
- ✓Biopsy-proven prostate adenocarcinoma
- ✓Locally advanced prostate cancer with biochemical relapse after radical prostatectomy and/or radiotherapy, OR hormonal treatment-naive advanced or metastatic prostate cancer without prior chemotherapy and no plans for chemotherapy at study entry
- ✓Physician has decided to initiate LHRH agonist treatment in standard clinical practice
- ✓Patient expects access to androgen deprivation therapy (ADT) after study completion within local healthcare system
Key exclusion· 10
- ✕Castrate-resistant prostate cancer
- ✕Prior treatment with LHRH analogues
- ✕Prior or concomitant systemic chemotherapy, or likelihood of receiving chemotherapy during study
- ✕Prior bilateral orchiectomy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
In Brief
A Phase 4 clinical trial evaluating Leuprolide for Prostate Cancer. Completed, enrolled 107 participants across 19 sites in 8 countries.
Detailed Summary
The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesHong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartJun 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedJan 27, 2017
Enrollment StartJun 23, 2017
Primary CompletionNov 19, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.4 years ago
Interventions
Leuprolidedrug
Subcutaneous Injection